veterinary-oncology
(2)
ImpriMed, Inc.
ImpriMed is a Palo Alto-based precision medicine company using live-cell drug sensitivity testing and AI to predict how individual cancer patients - starting with dogs and cats - will respond to specific chemotherapy drugs. Founded in 2017 by Stanford engineering PhDs Sungwon Lim and Jamin Koo, ImpriMed serves a network of 250+ veterinary oncologists and is expanding its platform into human blood cancers and pharma CRO services.
One Health Company (FidoCure)
One Health Company, known to vets and pet parents as FidoCure, brings human-grade precision oncology to dogs. It sequences canine tumors, pinpoints cancer-driving mutations, and uses an AI engine (Fetch) trained on the world's largest structured canine cancer dataset to recommend targeted, FDA-approved therapies. Because dog and human cancers share genetics, the company is also building a comparative-oncology data asset that could accelerate cancer drug development for both species.